Inj. naxitamab-gqgk, 1 mg
Products billed under this code include Danyelza.
Payment limit per 1 MG, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Danyelza.
Payment limit per 1 MG, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Danyelza | Y-mAbs Therapeutics, Inc. | 73042-0201-01 | 40 | $27,439.52 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $685.988 | +$1.09 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $684.898 | −$1.194 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $686.092 | +$0.009 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $686.083 | +$0.081 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $686.002 | +$0.096 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $685.906 | +$44.077 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $641.829 | −$0.46 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $642.289 | +$0.143 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $642.146 | +$32.978 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $609.168 | −$0.861 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $610.029 | +$0.264 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $609.765 | +$30.228 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $579.537 | −$0.112 | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $579.649 | – | 1 MG | Inj. naxitamab-gqgk, 1 mg | v1, posted June 5, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.